CytomX Therapeutics Investor Relations Material

CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. The company utilizes its proprietary Probody® platform to create antibody-based therapies that target cancer cells while minimizing damage to healthy tissues. CytomX’s approach aims to improve the safety and effectiveness of existing cancer therapies by activating its drugs only in the tumor microenvironment. The company's development pipeline includes therapeutic candidates designed for a variety of cancers, with the goal of addressing unmet medical needs in oncology. The company is headquartered in South San Francisco, California, and its shares are listed on the NASDAQ.